AIFA carries out monthly monitoring of pharmaceutical expenditure data and communicates the related results to the Ministry of Health and the Ministry of Economy and Finance with the same frequency.
The document is divided into 7 sections:
1. Verification of the Pharmaceutical Expenditure ceiling (7.96% of the national health requirement) calculated on the final 2019 FSN (amount equal to 113,791,926,183. The data is updated to 24 March 2020 as communicated by the MdS).
2. Verification of the Pharmaceutical Expenditure Ceiling for direct purchases net of medicinal gases (6.69% of the national health requirement) calculated on the final 2019 FSN.
3. Expenditure on Innovative drugs and verification of any excess expenditure with respect to the innovative non-oncological funds and the innovative oncological drug fund envisaged by Law 232 of 11 December 2016.
4. Verification of the Pharmaceutical Expenditure Ceiling for direct purchases of medicinal gases (0.20% of the national health requirement) calculated on the final 2019 FSN.
5. Overall pharmaceutical expenditure January-December 2019 and verification of compliance with overall resources.
6. Source of data.
7. Appendix.
The net approved pharmaceutical expenditure borne by the NHS in the period January-December 2019 calculated net of discounts, total sharing (regional tickets and sharing of the reference price) and the 1.83% payback paid to the Regions by pharmaceutical companies, amounted to 7,765.3 million euros (table 1 and column M of table 7), showing a decrease compared to the previous year (-16.2 million euros). Consumption, expressed in number of recipes (570.3 million recipes), shows a reduction (-1.0%) compared to 2018; the incidence of the total ticket also decreased (-1.6%).
Table 3 Summary of net subsidized pharmaceutical expenditure in the period January-December 2019, in the individual regions, compared to the same period of 2018
There table 4a indicates, for each Region, a set of indicators of expenditure and per capita consumption of the approved pharmaceutical, considering the weighted population for the year 2019.
For other useful information, see the AIFA text
by clicking here: complete document
Note: to enlarge the tables click on them
